Literature DB >> 18263797

Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism.

Mareike Lankeit1, Tibor Kempf, Claudia Dellas, Mayumi Cuny, Heike Tapken, Timo Peter, Manfred Olschewski, Stavros Konstantinides, Kai C Wollert.   

Abstract

RATIONALE: Growth differentiation factor (GDF)-15 is a cytokine induced in the heart after ischemia or pressure overload. Circulating levels of GDF-15 provide independent prognostic information in patients with acute coronary syndromes or heart failure.
OBJECTIVES: We investigated the prognostic value of GDF-15 in acute pulmonary embolism.
METHODS: In a prospective cohort study, plasma levels of GDF-15 were determined by immunoradiometric assay in 123 consecutive patients with confirmed acute pulmonary embolism.
MEASUREMENTS AND MAIN RESULTS: GDF-15 concentrations on admission ranged from 553 to 47,274 ng/L; 101 patients (82%) had GDF-15 levels above the upper limit of normal (1,200 ng/L). Patients who experienced pulmonary embolism-related complications during the first 30 days had higher baseline levels of GDF-15 (median, 6,039 [25th to 75th percentiles, 2,778 to 19,772] ng/L) compared with those with an uncomplicated course (median, 2,036 [25th to 75th percentiles, 1,279 to 3,176] ng/L; P < 0.001). By multivariable logistic regression analysis, which included clinical characteristics, cardiac biomarkers (troponin T and NT-proBNP [N-terminal propeptide of B-type natriuretic peptide]), and echocardiographic findings, GDF-15 emerged as an independent predictor of a complicated 30-day outcome (P = 0.033). The c-statistic for GDF-15 was 0.84 (95% confidence interval, 0.76-0.90), as compared with 0.72 for cardiac troponin T, and 0.65 for NT-proBNP. The ability of troponin T, NT-proBNP, and echocardiographic findings of right ventricular dysfunction to predict the risk of a complicated 30-day outcome was enhanced by GDF-15. Furthermore, multivariable Cox regression identified baseline levels of GDF-15 as an independent predictor of long-term mortality (P < 0.001).
CONCLUSIONS: GDF-15 is a promising new biomarker for risk stratification of pulmonary embolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263797     DOI: 10.1164/rccm.200712-1786OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

Review 1.  The development of gene therapy for diseases of the lung.

Authors:  D R Gill; L A Davies; I A Pringle; S C Hyde
Journal:  Cell Mol Life Sci       Date:  2004-02       Impact factor: 9.261

Review 2.  Biomarkers in heart failure: the past, current and future.

Authors:  Michael Sarhene; Yili Wang; Jing Wei; Yuting Huang; Min Li; Lan Li; Enoch Acheampong; Zhou Zhengcan; Qin Xiaoyan; Xu Yunsheng; Mao Jingyuan; Gao Xiumei; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

3.  Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Levent Cem Mutlu; Nejat Altintas; Murat Aydin; Feti Tulubas; Mustafa Oran; Volkan Kucukyalin; Gizem Kaplan; Ahmet Gurel
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

4.  Increased serum levels of GDF-15 associated with mortality and subclinical atherosclerosis in patients on maintenance hemodialysis.

Authors:  H Yilmaz; H T Çelik; O M Gurel; M A Bilgic; M Namuslu; H Bozkurt; A Ayyildiz; O Inan; N Bavbek; A Akcay
Journal:  Herz       Date:  2014-08-14       Impact factor: 1.443

5.  Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.

Authors:  Gang Li; Yan Li; Xiao-Qiu Tan; Peng Jia; Jian Zhao; Dong Liu; Ting Wang; Bin Liu
Journal:  Pediatr Cardiol       Date:  2017-08-18       Impact factor: 1.655

6.  The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction.

Authors:  Raoul Stahrenberg; Frank Edelmann; Meinhard Mende; Anke Kockskämper; Hans-Dirk Düngen; Claus Lüers; Lutz Binder; Christoph Herrmann-Lingen; Götz Gelbrich; Gerd Hasenfuss; Burkert Pieske; Rolf Wachter
Journal:  Eur J Heart Fail       Date:  2010-09-13       Impact factor: 15.534

Review 7.  Genomics of pulmonary arterial hypertension: implications for therapy.

Authors:  Mark W Geraci; Todd M Bull; Rubin M Tuder
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

Review 8.  Growth differentiation factor 15 in heart failure: an update.

Authors:  Kai C Wollert; Tibor Kempf
Journal:  Curr Heart Fail Rep       Date:  2012-12

Review 9.  Concise review: growth differentiation factor 15 in pathology: a clinical role?

Authors:  Jill Corre; Benjamin Hébraud; Philippe Bourin
Journal:  Stem Cells Transl Med       Date:  2013-11-04       Impact factor: 6.940

Review 10.  Prognostic stratification of acute pulmonary embolism: focus on clinical aspects, imaging, and biomarkers.

Authors:  Luca Masotti; Marc Righini; Nicolas Vuilleumier; Fabio Antonelli; Giancarlo Landini; Roberto Cappelli; Patrick Ray
Journal:  Vasc Health Risk Manag       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.